Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation
Maya Ghoussaini(Regeneron (United States)), Sofia Khan(University of Helsinki), Marjanka K. Schmidt(University of Cambridge), Guillermo Pita(Spanish National Cancer Research Centre), Hiltrud Brauch(German Cancer Research Center), Frederik Marmé(Heidelberg University), Sander Canisus(The Netherlands Cancer Institute), Peter A. Fasching(Universitätsklinikum Erlangen), Daniel C. Tessier(McGill University and Génome Québec Innovation Centre), Mahdi Moradi Marjaneh(NIHR Imperial Biomedical Research Centre), Thérèse Truong(Université Paris-Sud), Annegien Broeks, Joe Dennis(University of Cambridge), Jason S. Lee(The University of Queensland), Kenneth Muir(Manchester Academic Health Science Centre), Pascal Guénel(Inserm), Anna González‐Neira(Spanish National Cancer Research Centre), Ian Tomlinson(University of Oxford), Roger L. Milne(The University of Melbourne), Kyriaki Michailidou(Cyprus Institute of Neurology and Genetics), Ed Dicks(Institute of Cancer Research), Juliet D. French(The University of Queensland), Javier Benı́tez(Spanish National Cancer Research Centre), Silje Nord(Oslo University Hospital), Heli Nevanlinna(University of Helsinki), Susan L. Neuhausen(City of Hope), Elinor J. Sawyer(King's College London), Olivia Fletcher(Breast Cancer Care), Ute Hamann(German Cancer Research Center), Susanne Kaufmann(QIMR Berghofer Medical Research Institute), Stig E. Bojesen(University of Copenhagen), Artitaya Lophatananon(Manchester Academic Health Science Centre), Hermann Brenner(Universidad de Granada), Hoda Anton‐Culver(University of California, Irvine), Melissa C. Southey(The University of Melbourne), Daniel Vincent(The Netherlands Cancer Institute), Barbara Burwinkel(German Cancer Research Center), Matthias W. Beckmann, Haran Sivakumaran(QIMR Berghofer Medical Research Institute), John L. Hopper(The University of Melbourne), M. Rosario Alonso(Spanish National Cancer Research Centre), Rita K. Schmutzler(The University of Melbourne), Henrik Flyger(Herlev Hospital), Manjeet K. Bolla(University of Cambridge), Kristine M. Hillman(The University of Queensland), Alfons Meindl(Helmholtz Zentrum München), Nichola Johnson(Institute of Cancer Research), Jonathan Beesley(QIMR Berghofer Medical Research Institute), Volker Arndt(German Cancer Research Center)
Cited by 81
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
|JAMA Oncology|2016|6.3k
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
|The Lancet Public Health|2022|5.4k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k